share_log

Reported Sunday, Alnylam Reported Interim Phase 1 Results For Nucresiran (ALN-TTRsc04), Demonstrating Rapid And Sustained TTR Reduction Lasting Six Months After A Single Dose

Benzinga ·  Nov 18 01:49
  • Single Dose of Nucresiran 300mg or Higher Led to Rapid Knockdown of Mean TTR Levels of Greater than 90% by Day 15 that was Sustained at Six Months
  • At These Doses, Peak Reduction of Mean TTR Levels of Greater than 96% were Achieved by Day 29 −
  • Data Support Potential for Biannual or Annual Subcutaneous Dosing, Representing a New Paradigm in the Treatment of ATTR Amyloidosis −
  • Encouraging Safety and Tolerability Observed −
  • Alnylam Continues to Expect to Share Phase 3 Development Plans in Q1 2025 –
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment